				•									once, du	ing the repo	rting period v	vhen such transaction	was undert	aken.	Í
	Details of the party entition into the transaction	Pering Details of the con	nterparty		Date 1	Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials ind lake or give loai				Details o	of loans/ inv	estments	
S		Name	Relationship of the counterpart with the liste entity or its subsidiary	Transaction d	Details of other related party transactions	as	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1	Zydus Lifesciences Limit	d Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		8	Amount as approved by the Audit Committee.	8	-	-	-		-	-	-	-	-	-	-
2	Zydus Lifesciences Limit	d Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		97	Amount as approved by the Audit Committee.	97	-	-	-		-	-	-	-	-	-	-
3	Zydus Lifesciences Limit	d Zydus Healthcare S.A. (Pty	Ltd Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
4	Zydus Lifesciences Limit	d Zydus Nikkho Farmaceutic Ltda.	Subsidiary Company	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
	Zydus Lifesciences Limit	d Zydus Healthcare (USA) LLu	Subsidiary Company	Purchase of goods or services		6	Amount as approved by the Audit Committee.	6	-	-	-		-	-	-	-	-	-	-
6	Zydus Lifesciences Limit	d Zydus Hospira Oncology Private Limited	Joint Venture	S Purchase of goods or services		27	Amount as approved by the Audit Committee.	27	-	-	-		-	-	-	-	-	-	-
7	Zydus Lifesciences Limit	d Sterling Biotech Limited	Joint Venture	s Purchase of goods or services		9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
8	Zydus Lifesciences Limit	d Cadmach Machinery Comp Private Limited	Enterprises significantly any influenced by Directors and or their relatives	Purchase of goods or / services		9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
g	Zydus Lifesciences Limit	d Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and or their relatives	Purchase of goods or / services		318	Amount as approved by the Audit Committee.	318	-	-	-		-	-	-	-	-	-	-
1	Zydus Lifesciences Limit	d Zydus VTEC Limited	Subsidiary Company	Purchase of fixed assets		179	Amount as approved by the Audit Committee.	179	-	-	-		-	-	-	-	-	-	-

	Details of the party entering into	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		y financials indo	ebtedness is i	ncurred to	rung period v	vhen such transaction Details o	of loans/ inv		
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
11	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
12	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of fixed assets		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
13	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
14	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Purchase of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
15	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Purchase of goods or services		541	Amount as approved by the Audit Committee.	541	-	-	-		-	-	-	-	-	-	-
16	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Purchase of goods or services		29	Amount as approved by the Audit Committee.	29	-	-	-		-	-	-	-	-	-	-
17	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		8	Amount as approved by the Audit Committee.	8	-	-	-		-	-	-	-	-	-	-
18	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
19	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
20	Zydus Lifesciences Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		4	Amount as approved by the Audit Committee.	4		-	-		-	-	-	-	-	-	-

-		1		1		1		ı			-		once, dur	ring the repo	orting period w	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details (of loans/ inv	estments	
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
21	Zydus Lifesciences Limited	International Tax & Investment Consultants- Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
22	Zydus Lifesciences Limited	TUV India Private Limited	Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
23	Zydus Lifesciences Limited	Apollo Healthco Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-
24	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		51	Amount as approved by the Audit Committee.	51	-	-	-		-	-	-	-	-	-	-
25	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	383	Amount as approved by the Audit Committee.	383	-	-	-		-	-	-	-	-	-	-
26	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	19	Amount as approved by the Audit Committee.	19	-	-	-		-	-	-	-	-	-	-
27	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	19	Amount as approved by the Audit Committee.	19	-	-	-		-	-	-	-	-	-	-
28	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-
29	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	102	Amount as approved by the Audit Committee.	102		-	-		-	-	-	-	-	-	-
30	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	64	Amount as approved by the Audit Committee.	64	-	-	-		-	-	-	-	-	-	-

-	1				1		1					-		once, dur	ing the repo	rting period w	when such transaction	was underta	aken.	
	Details of the party en into the transaction	ering	Details of the counter	rparty			Value of the related		Value of	In case monies either party as the trans	s a result of		y financials indo ake or give loar				Details (of loans/ inv	estments	
S. No			Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
31	. Zydus Lifesciences Limit	ed Zyı	dus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
32	Zydus Lifesciences Limit		dus Nikkho Farmaceutica da.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	10	Amount as approved by the Audit Committee.	10	-	-	-		-	-	-	-	-	-	-
33	Zydus Lifesciences Limit	ed Zyı	dus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	10	Amount as approved by the Audit Committee.	10	-	-	-		-	-	-	-	-	-	-
34	Zydus Lifesciences Limit	ed He	dus Hospitals and Palthcare Research Private Mited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimburseme nt of Expenses paid	0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
35	Zydus Lifesciences Limit		dus Hospira Oncology ivate Limited	Joint Ventures	Any other transaction	Reimburseme nt of Expenses paid	53	Amount as approved by the Audit Committee.	53	-	-	-		-	-	-	-	-	-	-
36	Zydus Lifesciences Limit		dus Hospira Oncology ivate Limited	Joint Ventures	Any other transaction	Reimburseme nt of Expenses Recovered	5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-
37	Zydus Lifesciences Limit		dus Animal Health and vestments Limited	Subsidiary Company	Sale of goods or services		43	Amount as approved by the Audit Committee.	43	-	-	-		-	-	-	-	-	-	-
38	Zydus Lifesciences Limit	ed Zyı		Subsidiary Company	Sale of goods or services		213	Amount as approved by the Audit Committee.	213	-	-	-		-	-	-	-	-	-	-
39	Zydus Lifesciences Limit	ed Zyı	dus Healthcare Limited	Subsidiary Company	Sale of goods or services		347	Amount as approved by the Audit Committee.	347	-	-	-		-	-	-	-	-	-	-
40	Zydus Lifesciences Limit	ed Zyo		Subsidiary Company	Sale of goods or services		44,227	Amount as approved by the Audit Committee.	44,227	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans,
intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

													once, du	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of	In case an	y financials indo				Details o	of loans/ inv	estments	
S No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
4:	. Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		1,354	Amount as approved by the Audit Committee.	1,354	-	-	-		-	-	-	-	-	-	-
4:	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Sale of goods or services		337	Amount as approved by the Audit Committee.	337	-	-	-		-	-	-	-	-	-	-
43	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		203	Amount as approved by the Audit Committee.	203	-	-	-		-	-	-	-	-	-	-
44	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		455	Amount as approved by the Audit Committee.	455	-	-	-		-	-	-	-	-	-	-
4!	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		589	Amount as approved by the Audit Committee.	589	-	-	-		-	-	-	-	-	-	-
41	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Sale of goods or services		412	Amount as approved by the Audit Committee.	412	-	-	-		-	-	-	-	-	-	-
4	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Sale of goods or services		263	Amount as approved by the Audit Committee.	263	-	-	-		-	-	-	-	-	-	-
48	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Sale of goods or services		185	Amount as approved by the Audit Committee.	185	-	-	-		-	-	-	-	-	-	-
49	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		485	Amount as approved by the Audit Committee.	485	-	-	-		-	-	-	-	-	-	-
50	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		1,113	Amount as approved by the Audit Committee.	1,113	-	-	-		-	-	-	-	-	-	-

	•			•									once, du	ing the repo	rting period w	vhen such transaction	was undert	aken.	•
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	m	y financials indo				Details o	of loans/ inv	estments	
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
51	Zydus Lifesciences Limited	Zydus Takeda Healthcare Private Limited	Joint Ventures	Sale of goods or services		37	Amount as approved by the Audit Committee.	37	-	-	-		-	-	-	-	-	-	-
52	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		16	Amount as approved by the Audit Committee.	16	-	-	-		-	-	-	-	-	-	-
53	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
54	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limitec	Subsidiary Company	Sale of fixed assets		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
55	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of fixed assets		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
56	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Sale of goods or services		32	Amount as approved by the Audit Committee.	32	-	-	-		-	-	-	-	-	-	-
57	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of fixed assets		15	Amount as approved by the Audit Committee.	15	-	-	-		-	-	-	-	-	-	-
58	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
59	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		9	Amount as approved by the Audit Committee.	9	-	-	-		-	-	-	-	-	-	-
60	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-

-	1		ı		1			1						once, du	ing the repo	rting period w	when such transaction	was underta	iken.	
	Details of the pa into the trans	•	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials indo ake or give loar				Details (of loans/ inv	estments	
S Ne		ne	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
6	L Zydus Lifescience	es Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Sale of goods or services		5	Amount as approved by the Audit Committee.	5	-	-	-		-	-	-	-	-	-	-
6	2 Zydus Lifescience	es Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
6	3 Zydus Lifescience	es Limited	Zydus VTEC Limited	Subsidiary Company	Sale of goods or services		18	Amount as approved by the Audit Committee.	18	-	-	-		-	-	-	-	-	-	-
6-	1 Zydus Lifescience	es Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		264	Amount as approved by the Audit Committee.	264	-	-	-		-	-	-	-	-	-	-
6	5 Zydus Lifescience	es Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		15	Amount as approved by the Audit Committee.	15	-	-	-		-	-	-	-	-	-	-
6	5 Zydus Lifescience	es Limited	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		4	Amount as approved by the Audit Committee.	4	-	-	-		-	-	-	-	-	-	-
6	7 Zydus Lifescience	es Limited	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		33	Amount as approved by the Audit Committee.	33	-	-	-		-	-	-	-	-	-	-
6	3 Zydus Lifescience	es Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
6	O Zydus Lifescience	es Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		43	Amount as approved by the Audit Committee.	43	-	-	-		-	-	-	-	-	-	-
71) Zydus Lifescience	es Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		52	Amount as approved by the Audit Committee.	52	-	-	-		-	-	-	-	-	-	-

-	1	1		1							-		once, dur	ring the repo	orting period v	vhen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loa				Details (of loans/ inv	estments	
S. No	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
71	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	0			-	-	-	-	-	-	-
72	Zydus Lifesciences Limited	Zydus Medtech Private Limited	Subsidiary Company	Sale of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
73	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	62	Amount as approved by the Audit Committee.	62	-	-	-		-	-	-	-	-	-	-
74	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	128	Amount as approved by the Audit Committee.	128	-	-	-		-	-	-	-	-	-	-
75	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	7	Amount as approved by the Audit Committee.	7	-	-	-		-	-	-	-	-	-	
76	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
77	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	11	Amount as approved by the Audit Committee.	11	-	-	-		-	-	-	-	-	-	-
78	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
79	Zydus Lifesciences Limited	Mr. Pankaj R. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
80	Zydus Lifesciences Limited	Mr. Mukesh M. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans,
intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only

	•												once, dur	ing the repo	rting period v	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind lake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
81	Zydus Lifesciences Limited	Mr. Nitin Raojibhai Desai	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
82	Zydus Lifesciences Limited	Mr. Apurva S. Diwanji	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
83	Zydus Lifesciences Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
84	Zydus Lifesciences Limited	Ms. Shelina Parikh	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
85	Zydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
86	Zydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
87	Zydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
88	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Remuneration		-	N.A.	150	-	-	-		-	-	-	-	-	-	-
89	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Remuneration		-	N.A.	80	-	-	-		-	-	-	-	-	-	-
90	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Remuneration		-	N.A.	40	-	-	-		-	-	-	-	-	-	-
91	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
92	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-		<u> </u>	-	-	-	-		-	-

								•					once, du	ing the repo	rting period v	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		ny financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
93	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.	355	-	-	-		-	-	-	-	-	-	-
94	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	404	-	-	-		-	-	-	-	-	-	-
95	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.	149	-	-	-		-	-	-	-	-	-	-
96	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	276	-	-	-		-	-	-	-	-	-	-
97	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		7	Amount as approved by the Audit Committee.	7	-	-	-		-	-	-	-	-	-	-
98	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-		-
99	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Interest received		-	N.A.	1	-	-	-	†	-	-	-	-	-	-	-
100	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Interest paid		-	N.A.	41	-	-	-	†	-	-	-	-	-	-	-
101	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Interest paid		-	N.A.	725	-	-	-		-	-	-	-	-	-	-
102	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Interest paid		-	N.A.	1,294	-	-	-		-	-	-	-	-	-	-
103	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.	4,167	-	-	-		-	-	Loans	6 Month SOFR + 180 BPS	5 Years	Unsecured	Business Purpose
104	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Loan		-	N.A.	211	-	-	-		-	-	Loans	6 Month SONIA + 180 BPS	5 Years	Unsecured	Business Purpose
105	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
106	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	4	4	-		-	-	-	-	-	-	-
107	Zydus Lifesciences Limited	LM Manufacturing India Private Limited	Subsidiary Company	Investment		-	N.A.	-	0	-	-		-	-	-	-	-	-	-
108	Zydus Lifesciences Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Investment		-	N.A.	-	10,020	-	-		-	-	-	-	-	-	-
109	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Investment		-	N.A.	450	6,600	7,050	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
110	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Investment		-	N.A.	-	2,990	-	-		-	-	-	-	-	-	-
111	Zydus Lifesciences Limited	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Investment		-	N.A.	84	-	84	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
112	Zydus Lifesciences Limited	Zynext Ventures Pte. Ltd.	Subsidiary Company	Investment		-	N.A.	339	-	360	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
113	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Investment		-	N.A.	-	7,076	-	-		-	-	-	-	-	-	-
114	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Investment		-	N.A.	3,600	-	-	-		-	-	-	-	-	-	-
115	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Investment		-	N.A.	60	-	-	-		-	-	-	-	-	-	-
116	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Loan		-	N.A.	1,010	-	-	-		-	-	-	-	-	-	-
117	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Loan		-	N.A.	10,454	-	-	-		-	-	-	-	-	-	-
118	Zydus Lifesciences Limited	Cadila Healthcare Ltd. Managerial Cadre EPF	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	274	-	-	-		-	-	-	-	-	-	-

<u> </u>	T			1	1	1							once, du	ing the repo	rting period w	hen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
119	Zydus Lifesciences Limited	Cadila Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	16	-	-	-		-	-	-	-	-	-	-
120	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	22,504	11,670	-		-	-	-	-	-	-	-
121	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	33,824	36,638	-		-	-	-	-	-	-	-
122	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans		N.A.	-	1,037	1,037	-		-	-	-	-	-	-	-
123	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	196	470	-		-	-	-	-	-	-	-
124	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	135	-		-	-	-	-	-	-	-
125	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	275	401	-		-	-	-	-	-	-	-
126	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	408	733	-		-	-	-	-	-	-	-
127	Zydus Lifesciences Limited	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	31	37	-		-	-	-	-	-	-	-
128	Zydus Lifesciences Limited	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	2	1	-		-	-	-	-	-	-	-
129	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	89	75	-		-	-	-	-	-	-	-
130	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	283	302	-		-	-	-	-	-	-	-
131	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	44	48	-		-	-	-	-	-	-	-
132	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	48	60	-		-	-	-	-	-	-	-
133	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	210	273	-		-	-	-	-	-	-	-

-		T		1			1		г				once, dur	ing the repo	rting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
134	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	2	2	-		-	-	-	-	-	-	-
135	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Sale of goods or services		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
136	Zydus Lifesciences Limited	Zydus Lanka (Private) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	1	1	-		-	-	-	-	-	-	-
137	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	-	1	-		-	-	-	-	-	-	-
138	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	9	88	-		-	-	-	-	-	-	-
139	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	10	-		-	-	-	-	-	-	-
140	Zydus Lifesciences Limited	Sterling Biotech Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	-	15	-		-	-	-	-	-	-	-
141	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	48	61	-		-	-	-	-	-	-	-
142	Zydus Lifesciences Limited	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	1	1	-		-	-	-	-	-	-	-
143	Zydus Lifesciences Limited	Vitely Bio LLP	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	-	1	-		-	-	-	-	-	-	-
144	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
145	Zydus Lifesciences Limited	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	4	0	-		-	-	-	-	-	-	-
146	Zydus Lifesciences Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	81	141	-		-	-	-	-	-	-	-

	T			I	1	ı			ı				once, dur	ing the repo	rting period v	vhen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty		Data lla af	Value of the related	Dalia an	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loar				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
147	Zydus Lifesciences Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	12	25	-		-	-	-	-	-	-	-
148	Zydus Lifesciences Limited	TUV India Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
149	Zydus Lifesciences Limited	Aleta Hospitals LLP [Formerly known as Zydus Hospitals (Vadodara) LLP]	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
150	Zydus Lifesciences Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	130	-	-		-	-	-	-	-	-	-
151	Zydus Lifesciences Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	24	-	-		-	-	-	-	-	-	-
152	Zydus Lifesciences Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
153	Zydus Lifesciences Limited	Mr. Dhaval N. Soni	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
154	Zydus Lifesciences Limited	Mr. Mukesh M. Patel	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
155	Zydus Lifesciences Limited	Mr. Apurva S. Diwanji	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
156	Zydus Lifesciences Limited	Mr. Nitin Raojibhai Desai	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
157	Zydus Lifesciences Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
158	Zydus Lifesciences Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
159	Zydus Lifesciences Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
160	Zydus Lifesciences Limited	Mrs. Upasana Konidela	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-

	<u> </u>			ı				1	1				once, du	ing the repo	rting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty		D. 1. 1 (Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind nake or give loan				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
161	Zydus Lifesciences Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	2	2	-		-	-	-	-	-	-	-
162	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	-	230	-		-	-	-	-	-	-	-
163	Zydus Lifesciences Limited	Zydus International Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	12,993	13,405	-		-	-	-	-	-	-	-
164	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	13,758	13,822	-		-	-	-	-	-	-	-
165	Zydus Lifesciences Limited	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	1,251	5,445	-		-	-	-	-	-	-	-
166	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	9,445	9,765	-		-	-	-	-	-	-	-
167	Zydus Lifesciences Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	142	204	-		-	-	-	-	-	-	-
168	Zydus Lifesciences Limited	Zydus Wellness Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	7	4	-		-	-	-	-	-	-	-
169	Zydus Lifesciences Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	56	11	-		-	-	-	-	-	-	-
170	Zydus Lifesciences Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	5	4	-		-	-	-	-	-	-	-
171	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	41	104	-		-	-	-	-	-	-	-
172	Zydus Lifesciences Limited	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	1	3	-		-	-	-	-	-	-	-
173	Zydus Lifesciences Limited	Zydus Pharmaceuticals Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	396	595	-		-	-	-	-	-	-	-
174	Zydus Lifesciences Limited	Zydus VTEC Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	23	-	-		-	-	-	-	-	-	-
175	Zydus Lifesciences Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	33,153	37,989	-		-	-	-	-	-	-	-
176	Zydus Lifesciences Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	1,459	1,344	-		-	-	-	-	-	-	-
177	Zydus Lifesciences Limited	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	14	47	-		-	-	-	-	-	-	-

	Details of the party entering into	Details of the counte	rparty			Value of the			In case monie			y financials ind	ebtedness is i	ncurred to	orting period v	vhen such transaction Details o	of loans/ inv		
	the transaction		r		Details of	related party	Remarks on	Value of	the trans			ake or give loar	ns/ investmen	ts		I	,	1	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	other related party transactions	transaction as approved by the audit committee	approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
178	Zydus Lifesciences Limited	Zydus Healthcare Philippines Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	•	171	291	-		1	-	-	-	-	1	-
179	Zydus Lifesciences Limited	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	651	841	-		-	-	-	-	-	-	-
180	Zydus Lifesciences Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	637	908	-		-	-	-	-	-	-	-
181	Zydus Lifesciences Limited	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	848	877	-		-	-	-	-	-	-	-
182	Zydus Lifesciences Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	1,074	1,254	-		-	-	-	-	-	-	-
183	Zydus Lifesciences Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	717	716	-		-	-	-	-	-	-	-
184	Zydus Lifesciences Limited	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	76	76	-		-	-	-	-	-	-	-
185	Zydus Lifesciences Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	80	131	-		-	-	-	-	-	-	-
186	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	200	236	-		-	-	-	-	-	-	-
187	Zydus Lifesciences Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	3	-	-		-	-	-	-	-	-	-
188	Zydus Lifesciences Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	126	227	-		-	-	-	-	-	-	-
189	Zydus Lifesciences Limited	Bayer Zydus Pharma Private Limited		Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
190	Zydus Lifesciences Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	6	10	-		-	-	-	-	-	-	-
191	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-

													once, du	ring the repo	rting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the trans	s a result of	In case an	y financials indo				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
192	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	
193	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
194	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Directors and/ or their relatives	Purchase of goods or services		0	Amount as approved by the Audit Committee.	0	-	-	-		-	-	-	-	-	-	-
195	Zydus Healthcare Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
196	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Sale of goods or services		47	Amount as approved by the Audit Committee.	47	-	-	-		-	-	-	-	-	-	-
197	Zydus Healthcare Limited	Bayer Zydus Pharma Private Limited		Sale of goods or services		17	Amount as approved by the Audit Committee.	17	-	-	-		-	-	-	-	-	-	-
198	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		18	Amount as approved by the Audit Committee.	18	-	-	-		-	-	-	-	-	-	-
199	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Sale of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
200	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		8	Amount as approved by the Audit Committee.	8	-	-	-		-	-	-	-	-	-	-
201	Zydus Healthcare Limited	Mr. Harish Sadana	Key Managerial Personnel	Remuneration		-	N.A.	41	-	-	-		-	-	-	-	-	-	-
202	Zydus Healthcare Limited	Mr. Arvind Bothra	Key Managerial Personnel	Remuneration		-	N.A.	14	-	-	-		-	-	-	-	-	-	-

-									Ι.				once, dur	ing the repo	rting period v	vhen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty		Date that	Value of the related	D I	Value of	In case monie either party a the trans	s a result of	in case an	y financials ind ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
203	Zydus Healthcare Limited	Mr. Bhadresh K. Shah	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors		N.A.	0	-	-	-			-	-	-	-	-	-
204	Zydus Healthcare Limited	Mr. Sanjay Kumar Gupta	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
205	Zydus Healthcare Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
206	Zydus Healthcare Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
207	Zydus Healthcare Limited	Mr. Nitin D. Parekh	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
208	Zydus Healthcare Limited	Mr. Deevyesh J. Radia	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
209	Zydus Healthcare Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
210	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.	16	-	-	-		-	-	-	-	-	-	-
211	Zydus Healthcare Limited	Zydus Lifesciences Limited	Parent Company	Loan		-	N.A.	3,670	-	-	-		-	-	Loans	1 Month T Bill + 35 BPS	5 Years	Unsecured	Business Purpose
212	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	1,740	-	-	-		-	-	-	-	-	-	-
213	Zydus Healthcare Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
214	Zydus Healthcare Limited	Zydus Healthcare Limited Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	206	-	-	-		-	-	-	-	-	-	-

-	Т			1		T			T				once, du	ring the repo	orting period v	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	In case an	y financials ind lake or give loai				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
215	Zydus Healthcare Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
216	Zydus Healthcare Limited	Zydus Nikkho Farmaceutica Ltda.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	1	-		-	-	-	-	-	-	-
217	Zydus Healthcare Limited	Oneiro Chemicals Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
218	Zydus Healthcare Limited	Mr. Harish Sadana	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
219	Zydus Healthcare Limited	Mr. Arvind Bothra	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	1	-	-		-	-	-	-	-	-	-
220	Zydus Healthcare Limited	Mr. Deevyesh J. Radia	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
221	Zydus Healthcare Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
222	Zydus Healthcare Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
223	Zydus Healthcare Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	1,769	-	-		-	-	-	-	-	-	-
224	Zydus Healthcare Limited	Bayer Zydus Pharma Private Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	2	-	-		-	-	-	-	-	-	-
225	Zydus Healthcare Limited	German Remedies Pharma Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	6	-	-		-	-	-	-	-	-	-
226	Zydus Healthcare Limited	Ramanbhai Foundation	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
227	Zydus Healthcare Limited	Zydus Hospitals and Healthcare Research Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	5	11	-		-	-	-	-	-	-	-

	1						•						once, du	ing the repo	rting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials ind Iake or give loai				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
228	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of goods or services		57	Amount as approved by the Audit Committee.	57	-	-	-		-	-	-		-	1	-
229	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Purchase of fixed assets		2	Amount as approved by the Audit Committee.	2	-	-	-		-	-	-	-	-	-	-
230	Zydus Wellness Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		1	Amount as approved by the Audit Committee.	1	-	-	-		-	-	-	-	-	-	-
231	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		1,064	Amount as approved by the Audit Committee.	1,064	-	-	-		-	-	-	-	-	-	-
232	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		11	Amount as approved by the Audit Committee.	11	-	-	-		-	-	-	-	-	-	-
233	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Sale of goods or services		186	Amount as approved by the Audit Committee.	186	-	-	-		-	-	-	-	-	-	-
234	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	3	Amount as approved by the Audit Committee.	3	-	-	-		-	-	-	-	-	-	-
235	Zydus Wellness Limited	Dr. Sharvil P. Patel	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
236	Zydus Wellness Limited	Mr. Ganesh N. Nayak	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
237	Zydus Wellness Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-

					ı								once, dur	ing the repo	rting period v	vhen such transaction	was underta	iken.	
	Details of the party entering into the transaction	Details of the counter	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
238	Zydus Wellness Limited	Mr. Kulin Sanjay Lalbhai	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
239	Zydus Wellness Limited	Mr. Srivishnu Raju Nandayala	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
240	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.	7	-	-	-		-	-	-	-	-	-	-
241	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Remuneration		-	N.A.	11	-	-	-		-	-	-	-	-	-	-
242	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
243	Zydus Wellness Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
244	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Interest received		-	N.A.	78	-	-	-		-	-	-	-	-	-	-
245	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
246	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	80	-	-	-		-	-	Loans	1 Month T Bill + 50 BPS	1 year	Unsecured	Business Purpose
247	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.	42	-	-	-		-	-	Loans	6 Month SOFR + 150 BPS	2 years	Unsecured	Business Purpose
248	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.	21	-	-	-		-	-	Loans	6 Month SOFR + 150 BPS	2 years	Unsecured	Business Purpose
249	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Loan		-	N.A.	60	-	-	-		-	-	-	-	-	-	-
250	Zydus Pharmaceuticals Limited	Zydus Pharmaceuticals Limited Employees Group Gratuity Scheme		Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
251	Zydus Wellness Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	1	0	-		-	-	-	-	-	-	-
252	Zydus Wellness Limited	Mr. Akhil Monappa	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
253	Zydus Wellness Limited	Mr. Kulin Sanjay Lalbhai	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-

	,			ı			1		1		ļ		once, du	ing the repo	rting period v	vhen such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials ind lake or give loai				Details (of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
254	Zydus Wellness Limited	Mr. Savyasachi S. Sengupta	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
255	Zydus Wellness Limited	Mr. Srivishnu Raju Nandayala	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
256	Zydus Wellness Limited	Mr. Umesh V. Parikh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	1	1	-		-	-	-	-	-	-	-
257	Zydus Wellness Limited	Mr. Nandish P. Joshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
258	Zydus Wellness Limited	Ms. Dharmishta N. Raval	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
259	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	2,715	2,058	-		-	-	-	-	-	-	-
260	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	190	196	-		-	-	-	-	-	-	-
261	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	67	124	-		-	-	-	-	-	-	-
262	Zydus Wellness Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	11	20	-		-	-	-	-	-	-	-
263	Zydus Wellness Products Limited	Mukesh M. Patel & Co., Proprietorship Firm	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
264	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Remuneration		-	N.A.	40	-	-	-		-	-	-	-	-	-	-
265	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	118	-	-	-		-	-	-	-	-	-	-
266	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.	47	-	-	-		-	-	-	-	-	-	-
267	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	5	-	-	-		-	-	-	-	-	-	-
268	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services	1	-	N.A.	8	-	-	-		-	-	-	-	-	-	-
269	Zvdus Wellness Products	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	8	-	-	-		-	-	-	-	-	-	-
270	Zydus Weliness Products Limited	Heinz India Private Limited Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	11	-	-	-		-	-	-	-	-	-	-

	ı			T	1	1		1					once, dur	ing the repo	rting period v	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
271	Zydus Wellness Products Limited	Heinz India Private Limited Employee Provident Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	17	-	-	-		-	-	-	-	-	-	-
272	Zydus Wellness Products Limited	Heinz India Private Limited Pension Fund	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	2	-	-	-		-	-	-	-	-	-	-
273	Zydus Wellness Products Limited	Zydus Wellness Sikkim Employees Group Gratuity Scheme	Post Employment Benefit Plans	Any other transaction	Contributions during the year [includes Employee's share and contribution]	-	N.A.	3	-	-	-		-	-	-	-	-	-	-
274	Zydus Wellness Products Limited	Zydus Lifesciences Limited	Parent Company	Sale of fixed assets		-	N.A.	59	-	-	-		-	-	-	-	-	-	-
275	Zudus Wallpass Products	Cadmach Machinery Company Private Limited	Enterprises significantly	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
276	Zydus Wellness Products Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	2	-		-	-	-	-	-	-	-
277	Zydus Wellness Products Limited	Mr. Tarun Arora	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	2	3	-		-	-	-	-	-	-	-
278	Zydus Wellness Products Limited	Zydus Wellness International DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	81	187	-		-	-	-	-	-	-	-
279	Zydus Wellness Products Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	18	30	-		-	-	-	-	-	-	-
280	German Remedies Pharma Private Limited	Mr. Devanand Kumar Singh	Key Managerial Personnel	Remuneration	-	-	N.A.	8	-	-	-		-	-	-	-	-	-	-
281	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Sale of goods or services		-	N.A.	168	-	-	-		-	-	-	-		-	-
282	German Remedies Pharma Private Limited	Recon Pharmaceuticals and Investments	Subsidiary Company	Any other transaction	Share of profit Received	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
283	German Remedies Pharma Private Limited	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	1,037	-	-		-	-	-	-	-	-	-

Disclosure of related party transactions for the half year/ six months ended September 30, 2024

	1			ı		1	1	1	1				once, du	ring the repo	orting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind ake or give loa				Details	of loans/ inv	restments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
284	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	6	-	-		-	-	-	-	-	-	-
285	German Remedies Pharma Private Limited	Zydus Healthcare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	38	56	-		-	-	-	-	-	-	-
286	Zydus Pharmaceuticals Limited	Mr. Vishal Shah	Key Managerial Personnel	Remuneration		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
287	Zydus Pharmaceuticals Limited	Mr. Jignesh Thosani	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-	ļ	-	-	-	-	-	-	-
288	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	20	-	-	-		-	-	-	-	-	-	-
289	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		-	N.A.	55	-	-	-		-	-	-	-	-	-	-
290	Zydus Pharmaceuticals Limited	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	(7	-	-	-		-	-	-	-	-	-	-
291	Zydus Pharmaceuticals Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	3	10	-		-	-	-	-	-	-	-
292	Zydus Pharmaceuticals Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	7	-	-		-	-	-	-	-	-	-
293	Zydus Pharmaceuticals Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	49	-		-	-	-	-	-	-	-
294	Zydus VTEC Limited	Mr. Pranjal Jyoti Sharma	Key Managerial Personnel	Remuneration		-	N.A.	3	-	-	-		-	-	-	-	-	-	-
295	Zydus VTEC Limited	Mr. Daivat Navanit Vakil	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
296	Zydus VTEC Limited	Ms. Dishita Udit Shah	Key Managerial Personnel	Remuneration		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
297	Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
298	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Interest received		-	N.A.	0	-	-	-			-	-	-	-	-	-
299	Zydus Animal Health and Investments Limited	Dialforhealth Unity Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
300	Investments Limited	Sterling Biotech Limited	Joint Ventures	Investment		-	N.A.	6,500	-	6,500	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
301	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Investment	<u>[</u>	-	N.A.	378	-	419	<u> </u>	<u> </u>	-	-	Investment	N.A	N.A	Unsecured	Business Purpose

													once, du	ing the repo	orting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	erparty			Value of the related		Value of	In case monie either party a the tran	s a result of	In case an	y financials ind lake or give loai				Details	of loans/ inv	restments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
302	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Investment		-	N.A.	245	-	245	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
303	Zvdus Animal Health and	Zydus Medtech Private Limited	Subsidiary	Interest received		-	N.A.	12	-	-	-	 	-	-		-	-	-	-
304	Zydus Animal Health and	Zydus Medtech Private	Company Subsidiary	Loan			N.A.	636							Loans	1 Month T Bill + 120	5 Years	Unsecured	Business Purpose
	Investments Limited	Limited	Company		Outstanding	 -	ļ		 	 		 	 		200115	BPS	J rears	- Onsecured	
305	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Receivables - Other than loans	-	N.A.	-	-	4	-		-	-	-	-	-	-	-
306	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
307	Zydus Animal Health and	ZyVet Animal Health Inc	Subsidiary	Sale of goods or services		-	N.A.	1,123	-	-	-		-	-	-	-	-	-	-
308	Investments Limited Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Company Subsidiary Company	Interest received		-	N.A.	12	-	-	-		-	-	-	-	-	-	-
309	Zydus Animal Health and Investments Limited	Mr. Pramod Lokhande	Key Managerial Personnel	Remuneration		-	N.A.	2	-	-	-		-	-	-	-	-	-	-
310	Zydus Animal Health and Investments Limited	Mr. Hiren Mistry	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
311	Zydus Animal Health and Investments Limited	Mr. Mihir J. Mehta	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
312	German Remedies Pharma Private Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
313	Zydus Animal Health and Investments Limited	Dr. Bhavna Doshi	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
314	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	91	51	-		-	-	-	-	-	-	-
315	Zydus Animal Health and Investments Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
316	Zydus Animal Health and Investments Limited	Zydus Infrastructure Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than Ioans	-	N.A.	-	1	-	-		-	-	-	-	-	-	-
317	Zydus Animal Health and Investments Limited	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	417	419	-		-	-	-	-	-	-	-
318	Zydus Animal Health and Investments Limited	Zydus Medtech Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	-	647	-		-	-	-	-	-	-	-
319	Zydus Animal Health and Investments Limited	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than	-	N.A.	-	493	932	-		-	-	-	-	-	-	-
L	L	J	.J	L	loans	J	<u> </u>	L	J	L	J	l	L	l	·	J		J	LJ

													once, dur	ing the repo	rting period v	when such transaction	was undert	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials indo ake or give loar	ebtedness is i	ncurred to			of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
320	Zydus Animal Health and Investments Limited	Zydus Lifesciences Limited	Parent Company	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	1	-	-		-	-	-	-	-	-	-
321	Recon Pharmaceuticals and Investments	Zydus Foundation	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
322	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	9	-	-	-		-	-	-	-	-	-	-
323	Zydus Pharmaceuticals (USA) Inc.	Navinta III, Inc	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	61	-	-	-		-	-	-	-	-	-	-
324	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	31	-	-	-		-	-	-	-	-	-	-
325	Zydus Pharmaceuticals (USA) Inc.	Navinta NV, Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	58	-	-	-		-	-	-	-	-	-	-
326	Zydus Pharmaceuticals (USA)	Sentynl Therapeutics Inc.	Subsidiary Company	Sale of goods or services			N.A.	3	-	-	-		-	-	-		-	-	-
327	Zydus Pharmaceuticals (USA)	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-				-	-	-	-	-	-
328	Zydus Pharmaceuticals (USA)	ZyVet Animal Health Inc	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-			-	-	-	-	-	-	-
329	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Purchase of goods or services		-	N.A.	5,923	-	-	-		-	-	-	-	-	-	-
330	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1,368	-	-	-		-	-	-	-	-	-	-
331	Zydus Pharmaceuticals (USA) Inc.	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Joans	-	N.A.	-	2	2,775	-		-	-	-	-	-	-	-
332	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
333	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	10	-	-	-		-	-	-	-	-	-	-
334	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-

	Details of the party entering								In case monie	s are due to					rting period v	when such transaction	was undert	акеп.	
	into the transaction	Details of the counte	rparty			Value of the related		Value of	either party a the trans	s a result of		y financials ind ake or give loar				Details o	of loans/ inv	estments	
S. No		Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
335	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
336	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	46	-	-	-		-	-	-	-	-	-	-
337	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
338	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
339	Zydus Pharmaceuticals (USA) Inc.	Mahadev Management Inc.	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	5	-	-	-		-	-	-	-	-	-	-
340	Zydus Pharmaceuticals (USA) Inc.	Zydus Healthcare (USA) LLC	Subsidiary Company	Interest received		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
341	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Interest received		-	N.A.	196	-	-	-		-	-	-	-	-	-	-
342	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Interest received		-	N.A.	19	-	-	-		-	-	-	-	-	-	-
343	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Interest received		-	N.A.	3	-	-	-		-	-	-	-	-	-	-
344	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Interest received		-	N.A.	167	-	-	-		-	-	-	-	-	-	-
345	inc.	Zydus Pharmaceuticals Canada Inc.		Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	1	-	-	-		-	-	-	-	-	-	-
346	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Interest received		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
347	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Loan		-	N.A.	8	-	-	-		-	-	Loans	3 Month SOFR + 50 bps	2 Year	Unsecured	Business Purpose
348	Zydus Pharmaceuticals (USA) Inc.	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	- -	8	-		- -	-	-	-	-	-	-
349	Inc.	Zydus Pharmaceuticals Canada Inc.	Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
350	Inc.	Zydus Therapeutics INC	Subsidiary Company	Loan		-	N.A.	1,602	-	-	-		-	-	Loans	6 Month SOFR + 50 bps	1 Year	Unsecured	Business Purpose
351	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.	4,514	-	-	-		-	-	Loans	6 Month SOFR + 50 bps	1 Year	Unsecured	Business Purpose
352	Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Loan		-	N.A.	4,180	-	-	-		-	-	-	-	-	-	-
353	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Loan		-	N.A.	247	-	-	-		-	-	-	-	-	-	-
354	Zydus Pharmaceuticals (USA) Inc.	NAI Laboratories Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	21	-	-			-	-	-	-	-	-

	ı				1				1				once, dur	ing the repo	rting period w	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	in case an	y financials indo ake or give loar				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
355	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	-	18			-	-	-	-	-	-	-
356	Zydus Pharmaceuticals (USA) Inc.	Navinta LLC	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	1	-	-		-	-	-	-	-	-	-
357	Zydus Pharmaceuticals (USA) Inc.	Nesher Pharmaceuticals (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	9,134	9,176	-		-	-	-	-	-	-	-
358	inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	6,257	6,716	-		-	-	-	-	-	-	-
359	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Loan		-	N.A.	13	-	-	-		-	-	-	-	-	-	-
360	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	747	738	-		-	-	-	-	-	-	-
361	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	246	-	-		-	-	-	-	-	-	-
362	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	4,775	6,404	-		-	-	-	-	-	-	-
363	Zydus Pharmaceuticals (USA) Inc.	Sentynl Therapeutics Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	88	2	-		-	-	-	-	-	-	-
364	Zydus Pharmaceuticals (USA) Inc.	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	8	61	-		-	-	-	-	-	-	-
365	Zydus Pharmaceuticals (USA) Inc.	ZyVet Animal Health Inc	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	4	1	-		-	-	-	-	-	-	-
366	Zydus Pharmaceuticals (USA) Inc.	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	42	30	-		-	-	-	-	-	-	-
367	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	2,456	-	-	-		-	-	-	-	-	-	-
368	Zydus Worldwide DMCC	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	2	-	-	-		-	-	-	-	-	-	-
369	Zydus Lifesciences Global FZE [UAE]	Mr. Pradeep Agnihotri	Key Managerial Personnel	Any other transaction	Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-

				I	ı	1	1	1	1				once, du	ing the repo	orting period v	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
370	Zydus Worldwide DMCC	Mr. Pradeep Agnihotri	Key Managerial Personnel		Director Sitting Fees and Commission to non executive directors	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
371	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services	uncetors	-	N.A.	1,382	-	-	-		-	-	-	-	-	-	-
372	Zydus Worldwide DMCC	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.	56	-	-	-		-	-	-	-	-	-	-
373	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.	27	-	-	-		-	-	-	-	-	-	-
374	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Interest received		-	N.A.	15	-	-	-		-	-	-	-	-	-	-
375	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Loan		-	N.A.	33	-	-	-		-	-	Loans	6 Month SOFR + 125 BPS	3 Years	Unsecured	Business Purpose
376	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	-	70	-		-	-	-	-	-	-	-
377	Zydus Worldwide DMCC	Etna Biotech S.R.L.	Subsidiary Company	Loan		-	N.A.	22	-	-	-		-	-	Loans	6 Month SOFR + 125 bps	5 Years	Unsecured	Business Purpose
378	Zydus Worldwide DMCC	Zydus International Private Limited	Subsidiary Company	Interest received		-	N.A.	296	-	-	-		-	-	-	-	-	-	-
379	Zydus Worldwide DMCC	Alidac Healthcare (Myanmar) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	478	528	-		-	-	-	-	-	-	-
380	Zydus Worldwide DMCC	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	907	938	-		-	-	-	-	-	-	-
381	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Joans	-	N.A.	-	641	206	-		-	-	-	-	-	-	-
382	Zydus Worldwide DMCC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	730	1,571	-		-	-	-	-	-	-	-
383	Zydus Therapeutics INC	Mr. Deven Parmar	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	1	-	-		-	-	-	-	-	-	-
384	Viona Pharmaceuticals INC	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
385	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
386	Viona Pharmaceuticals INC	Zydus Pharmaceuticals Canada Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
387	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services	-	-	N.A.	18	-	-	-		-	-	-	-	-	-	-
388	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-	-		-	-	-	-	-	-	-
389	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
			·			·												·	

Details of loans/ investments Secured/ Unsecured Purpose for with e funds will utilised by tultimate reciping funds (endus).
te (%) Tenure Secured/ Unsecured the funds wil utilised by tultimate reciping funds (endus)
- - -

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the trans	s a result of	In case an	y financials indo ake or give loar	ebtedness is i	ncurred to	Time period	Details o	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
405	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	838	-	-	-		-	-	-	-	-	-	-
406	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Interest received		-	N.A.	307	-	-	-		-	-	-	-	-	-	-
407	Zydus International Private Limited	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	9,600	8,801	-		-	-	-	-	-	-	-
408	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Interest received		-	N.A.	509	-	-	-		-	-	-	-	-	-	-
409	Zydus International Private Limited	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	17,168	17,771	-		-	-	-	-	-	-	-
410	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	9,603	8,947	-		-	-	-	-	-	-	-
411	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans Outstanding	-	N.A.	-	237	252	-		-	-	-	-	-	-	-
412	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Receivables - Loans	-	N.A.	-	346	365	-		-	-	-	-	-	-	-
413	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans Outstanding	-	N.A.	-	424	450	-		-	-	-	-	-	-	-
414	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Receivables - Loans	-	N.A.	-	316	334	-		-	-	-	-	-	-	-
415	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
416	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	0	-		-	-	-	-	-	-	-
417	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	398	440	-		-	-	-	-	-	-	-
418	Zydus Healthcare S.A. (Pty) Ltd	Alidac Pharmaceuticals SA (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	48	53	-		-	-	-	-	-	-	-
419	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.	254	-	-	-		-	-	-	-	-	-	-
420	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses Recovered	-	N.A.	0	-	-	-		-	-	-	-	-	-	-
421	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	3	-		-	-	-	-	-	-	-
422	Zydus Pharmaceuticals Mexico SA De CV	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Subsidiary Company	Purchase of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
423	Zydus Healthcare Philippines Inc.	RJ Conception Law Office	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-

	,	T		1		•	1	1					once, du	ring the repo	orting period v	when such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related		Value of	In case monie either party a the tran	s a result of		y financials ind nake or give loa				Details o	of loans/ inv	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
424	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Purchase of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
425	Alidac Healthcare (Myanmar) Limited	Cadmach Machinery Company Private Limited	Enterprises significantly influenced by Directors and/ or their relatives	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	1	-		-	-	-	-	-	-	-
426	Zynext Ventures Pte. Ltd.	Zynext Ventures USA LLC	Subsidiary Company	Investment		-	N.A.	334	19	354	-		-	-	Investment	N.A	N.A	Unsecured	Business Purpose
427	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Interest received		-	N.A.	49	-	-	-	ļ	-	-	-	-	-	-	-
428	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Interest received	ļ	-	N.A.	0	-	-	-	ļ	-	-	-	-	-	-	-
429	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Interest received		-	N.A.	109	-	-	-	ļ	-	-	-	-	-	-	-
430	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures Subsidiary	Interest received	ļ	-	N.A.	0	-	-	-	ļ	-	- 	-	-	-	-	-
431	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Company	Interest paid	Outstanding		N.A.	1	-	-	-	ļ	-	-	-	-	-	-	-
432	Zydus Pharmaceuticals UK Ltd.	Oncosol Limited	Joint Ventures	Any other transaction	Receivables - Loans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
433	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
434	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	1,626	1,840	-		-	-	-	-	-	-	-
435	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.	-	19	22	-		-	-	-	-	-	-	-
436	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.	-	731	830	-		-	-	-	-	-	-	-
437	Zydus Pharmaceuticals UK Ltd.	LiqMeds Worldwide Limited	Subsidiary Company	Investment		-	N.A.	-	3,029	-	-		-	-	-	-	-	-	-
438	Zydus Pharmaceuticals UK Ltd.	LiqMeds Limited	Subsidiary Company	Investment		-	N.A.	-	657	-	-	<u> </u>	-	-	-	-	-	-	-
439	Zydus Pharmaceuticals UK Ltd.	Medsolutions (Europe) Limited	Subsidiary Company	Investment		-	N.A.	-	118	-	-	ļ	-	-	-	-	-	-	-
440	Zydus Pharmaceuticals UK Ltd.	LiqMeds Lifecare Limited	Subsidiary Company Subsidiary	Investment		-	N.A.	-	128	-	-	<u> </u>	-	-	-	-	-	-	-
441	Zydus Pharmaceuticals UK Ltd.	LM Manufacturing Limited	Company	Investment	Outstanding		N.A.	-	832	-		ļ	-	-	-	-	-	-	-
442	[UAE]	Zydus Lifesciences Limited	Parent Company	Any other transaction	Payables - Other than loans	-	N.A.	-	155	1,044	-		-	-	-	-	-	-	-
443	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Sale of goods or services		-	N.A.	129	-	-	-		-	-	-	-	-	-	-
444	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Purchase of goods or services	<u> </u>	-	N.A.	7	-	-	-		-	-	-	-	-	-	-
445	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Reimburseme nt of Expenses paid	-	N.A.	4	-	-	-		-	-	-	-	-	-	-
		·	·	*	·	·			·^	·		·		·	·	,	*	·	·

	Details of the party entering into the transaction	Details of the counte	rparty			Value of the related			In case monie either party a the trans	s a result of		y financials indo	ebtedness is i	ncurred to	orting period v	vhen such transaction Details	of loans/ inv		
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	Details of other related party transactions	party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
446	Zydus Lifesciences Global FZE [UAE]	Zydus Healthcare (USA) LLC	Subsidiary Company	Any other transaction	Outstanding Payables - Other than Joans	-	N.A.	-	-	7	-			-	-	-	-	-	-
447	Zydus Lifesciences Global FZE [UAE]	Viona Pharmaceuticals INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	222	128	-		-	-	-	-	-	-	-
448	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.	10	-	-	-		-	-	-	-	-	-	-
449	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
450	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.	4	-	-	-		-	-	-	-	-	-	-
451	LM Manufacturing Limited	Zydus Pharmaceuticals UK Ltd.	Subsidiary Company	Sale of goods or services		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
452		Oncosol Limited	Joint Ventures	Sale of goods or services		-	N.A.	43	-	-	-		-	-	-	-	-	-	-
453	LM Manufacturing India Private Limited	LM Manufacturing Limited	Subsidiary Company	Sale of goods or services		-	N.A.	30	-	-	-		-	-	-	-	-	-	-
454	LiqMeds Worldwide Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	18	437	-		-	-	-	-	-	-	-
455	LiqMeds Worldwide Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
456	LM Manufacturing Limited	LM Manufacturing India Private Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	0	-	-		,	-	-	-	-	-	-
457	LM Manufacturing Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Ioans	-	N.A.	-	-	6	-		-	-	-	-	-	-	-
458	LM Manufacturing Limited	LiqMeds Lifecare Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	29	-	-		-	-	-	-	-	-	-
459	LM Manufacturing Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	1	8	-		-	-	-	-	-	-	-
460	LiqMeds Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	117	230	-		-	-	-	-	-	-	-
461	LiqMeds Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	57	57	-		-	-	-	-	-	-	-
462	LiqMeds Lifecare Limited	LM Manufacturing Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	26	-		-	-	-	-	-	-	-
463	LiqMeds Lifecare Limited	LiqMeds Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than Joans	-	N.A.	-	-	1	-		-	-	-	-	-	-	-

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, intercorporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

													once, du	ring the repo	rting period v	vhen such transaction	was underta	aken.	
	Details of the party entering into the transaction	Details of the counter	rparty		Details of	Value of the related party	Remarks on	Value of	In case monies either party as the trans	s a result of	m	y financials ind lake or give loa				Details o	of loans/ inve	estments	
S. No.	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Type of Related Party Transaction	other related party transactions		approval by audit	transaction during the reporting period	Opening balance	Closing balance	Nature of indebtedn ess (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorpora te deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
464	LiqMeds Lifecare Limited	Medsolutions (Europe) Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	10	-		-	-	-	-	-	-	-
465	LiqMeds Lifecare Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	4	-		-	-	-	-	-	-	-
466	Medsolutions (Europe) Limited	LiqMeds Worldwide Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.	-	-	13	-		-	-	-	-	-	-	-
467	Medsolutions (Europe) Limited	Oncosol Limited	Joint Ventures	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	0	-		-	-	-	-	-	-	-
468	Zydus Medtech Private Limited	Mr. Girishankar Gopalakrishnan	Key Managerial Personnel	Remuneration		-	N.A.	1	-	-	-		-	-	-	-	-	-	-
469	Zydus Medtech Private Limited		Key Managerial Personnel	Remuneration		-	N.A.	0	-	-	-		-	-	-	-	-	-	-
470	Zydus Healthcare Limited		Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
471	German Remedies Pharma Private Limited	Mr. Devanand Kumar Singh	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	1	-	-		-	-	-	-	-	-	-
472	Zydus Pharmaceuticals Limited	Mr. Vishal Shah	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
473	Zydus Pharmaceuticals Limited	Mr. Jignesh Thosani	Key Managerial Personnel	Any other transaction	Outstanding Payables - Other than loans	-	N.A.	-	0	-	-		-	-	-	-	-	-	-
474	Zydus Worldwide DMCC	Zydus Lifesciences Global FZE [UAE]	Subsidiary Company	Sale of goods or services		-	N.A.	205	-	-	-	<u> </u>	-	-	-	-	-	-	-
475	Zydus Healthcare S.A. (Pty) Ltd	DI Consultancy	Enterprises significantly influenced by	Purchase of goods or services		-	N.A.	6	-	-	-		-	-	-	-	-	-	-
476	Zydus Wellness Limited	Zydus Wellness Products Limited	Subsidiary Company	Loan		-	N.A.	745	-	-	-		-	-	-	-	-	-	-
477	Zydus Foundation	Zydus Hospira Oncology Private Limited	Joint Ventures	Any other transaction	Contributions received	-	N.A.	4	-	-	-		-	-	-	-	-	-	-
1			l		1	l	1	l	1		1	I	I	ı		l	ı	ı	ı

Notes:

- 1 Amount mentioned as 0 denotes value less than INR 1 Million.
- 2 Opening and closing balance are not given where there was no transaction of Investment during the half year ended September 30, 2024.
- 3 Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.
- 4 Zydus Lifesciences Limited had sold its entire stake from Bayer Zydus Pharma Private Limited as on May 2, 2024, hence the transactions upto May 2, 2024 are reported.